Molecular Partners AG (OTCMKTS:MLLCF) Short Interest Up 36.4% in September
Molecular Partners AG (OTCMKTS:MLLCF) Short Interest Up 36.4% in September
Molecular Partners AG (OTCMKTS:MLLCF – Get Rating) saw a large increase in short interest in September. As of September 30th, there was short interest totalling 171,900 shares, an increase of 36.4% from the September 15th total of 126,000 shares. Based on an average daily volume of 400 shares, the short-interest ratio is currently 429.8 days.
分子合作伙伴股份公司(OTCMKTS:MLLCF-GET Rating)看到空頭股數在9月份大幅增長。截至9月30日,空頭股數共有17.19萬股,比9月15日的12.6萬股增加了36.4%。以日均成交量400股計算,目前短息比率為429.8天。
Molecular Partners Stock Performance
分子合作伙伴股票表現
Shares of MLLCF stock traded down $0.31 on Monday, hitting $5.98. 500 shares of the stock traded hands, compared to its average volume of 1,428. Molecular Partners has a 1-year low of $5.16 and a 1-year high of $32.00. The company's fifty day moving average is $5.83 and its 200 day moving average is $8.03.
MLLCF股票週一下跌0.31美元,觸及5.98美元。該股有500股易手,而其平均成交量為1,428股。Molecal Partners的一年低點為5.16美元,一年高位為32.00美元。該公司的50日移動均線切入位在5.83美元,200日移動均線切入位在8.03美元。
Analysts Set New Price Targets
分析師設定新的價格目標
Separately, Credit Suisse Group cut their target price on Molecular Partners from CHF 8 to CHF 6 in a research report on Thursday, July 21st.
另外,瑞士信貸集團在7月21日星期四的一份研究報告中將分子合作伙伴的目標價從8瑞士法郎下調至6瑞士法郎。
About Molecular Partners
關於分子夥伴
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.
分子夥伴公司是一家臨牀階段的生物製藥公司,專注於治療性蛋白質的發現、開發和商業化。它的候選產品包括用於治療新血管濕性老年性黃斑變性和糖尿病黃斑水腫的候選DARPin藥物Abempar,該藥物處於第三階段臨牀試驗;以及針對SARS-CoV-2病毒的多特異性DARPin候選藥物MP0420。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Molecular Partners (MLLCF)
- Fisker is Entering a Critical Stage That Could Reward Investors
- The Bottom Is In For JPMorgan Chase & Co.
- The Institutions May Cap Gains In Steel Dynamics
- Watch These 3 Economic Reports to Impact Interest Rate Hikes
- Here are 3 Stocks That Benefit From a Strong U.S. Dollar
- 免費獲取StockNews.com關於分子夥伴的研究報告(MLLCF)
- 菲斯克正在進入一個關鍵階段,這可能會給投資者帶來回報
- 摩根大通的日子不好過了。
- 這些機構可能會限制鋼鐵動力領域的收益
- 請看以下3份經濟報告,以影響加息
- 以下是3只受益於強勢美元的股票
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
每日收到分子合作伙伴的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊,接收分子合作伙伴和相關公司的最新新聞和分析師評級的每日摘要。